Chunghwa Chemical Synthesis & Biotech (TWSE:1762) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

1762 Panoramica delle azioni

Chunghwa Chemical Synthesis & Biotech Co., Ltd.

1762 analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	0/6
Prestazioni passate	2/6
Salute finanziaria	5/6
Dividendi	2/6

Premi

Analisi del rischio

Il dividendo di 1.81% non è ben coperto dai flussi di cassa liberi

I margini di profitto (7.8%) sono inferiori rispetto allo scorso anno (17.4%)

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Concorrenti

Orient EuroPharma

TPEX:4120

NT$4.4b

Syngen BiotechLtd

TPEX:8279

NT$3.6b

SYN-TECH Chem. & Pharm

TPEX:1777

NT$4.4b

Genovate Biotechnology

TPEX:4130

NT$2.6b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Chunghwa Chemical Synthesis & Biotech
Prezzi storici delle azioni
Prezzo attuale dell'azione	NT$43.70
Massimo di 52 settimane	NT$63.10
Minimo di 52 settimane	NT$40.70
Beta	0.74
1Variazione di 1 mese	5.17%
Variazione a 3 mesi	-16.12%
Variazione di 1 anno	-25.55%
3Variazione a 3 anni	-44.12%
Variazione a 5 anni	31.63%
Variazione dall'IPO	-41.73%

Notizie e aggiornamenti recenti

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry

Aug 09

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80

Jul 12

Recent updates

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry

Aug 09

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80

Jul 12

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 04

A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Apr 01

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Mar 04

What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend

Jan 28

Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?

Jan 02

The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It

Dec 06

Rendimenti per gli azionisti

	1762	TW Pharmaceuticals	TW Mercato
7D	2.3%	-3.0%	-2.2%
1Y	-25.6%	11.9%	33.6%

Ritorno vs Industria: 1762 ha avuto una performance inferiore rispetto al TW Pharmaceuticals che ha registrato un rendimento 15.5 % nell'ultimo anno.

Rendimento vs Mercato: 1762 ha avuto una performance inferiore al mercato TW che ha registrato un rendimento 35.7 % nell'ultimo anno.

Volatilità dei prezzi

Is 1762's price volatile compared to industry and market?
1762 volatility
1762 Average Weekly Movement	4.1%
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	5.7%
10% most volatile stocks in TW Market	9.3%
10% least volatile stocks in TW Market	3.1%

Prezzo delle azioni stabile: 1762 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 4% ) di 1762 è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1964	n/a	Chung-Hsin Huang	www.ccsb.com.tw

Chunghwa Chemical Synthesis & Biotech Co., Ltd. si occupa di ricerca, sviluppo, produzione e vendita di ingredienti farmaceutici attivi (API) a Taiwan e negli Stati Uniti. Offre prodotti API, tra cui immunosoppressori, oncologici, antivirus, immunomodulanti e altri prodotti, nonché farmaci peptidici.

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Chunghwa Chemical Synthesis & Biotech con la sua capitalizzazione di mercato?
1762 statistiche fondamentali
Capitalizzazione di mercato	NT$3.39b
Guadagni(TTM)	NT$117.69m
Ricavi(TTM)	NT$1.51b

28.8x

Rapporto P/E

2.2x

Rapporto P/S

1762 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
1762 Conto economico (TTM)
Ricavi	NT$1.51b
Costo del fatturato	NT$1.02b
Profitto lordo	NT$487.29m
Altre spese	NT$369.59m
Guadagni	NT$117.69m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	1.52
Margine lordo	32.33%
Margine di profitto netto	7.81%
Rapporto debito/patrimonio netto	29.9%

Come si è comportato 1762 nel lungo periodo?

Vedi performance storica e confronto

Dividendi

1.8%

Rendimento attuale del dividendo

53%

Rapporto di remunerazione

1762 Panoramica delle azioni

Premi

Analisi del rischio

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Concorrenti

TPEX:4120

NT$4.4b

TPEX:8279

NT$3.6b

TPEX:1777

NT$4.4b

TPEX:4130

NT$2.6b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

New minor risk - Market cap size

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Dividend sustainability

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry

Chunghwa Chemical Synthesis & Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80

Recent updates

New minor risk - Market cap size

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Dividend sustainability

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry

Chunghwa Chemical Synthesis & Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80

Dividend reduced to NT$0.80

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Elects Hou-Kai as Vice Chairman

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Chunghwa Chemical Synthesis & Biotech Co., Ltd. to Report Q1, 2024 Results on May 09, 2024

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Full year 2023 earnings: EPS and revenues miss analyst expectations

Chunghwa Chemical Synthesis & Biotech Co., Ltd., Annual General Meeting, May 30, 2024

Insufficient new directors

New minor risk - Profit margin trend

Second quarter 2023 earnings: Revenues in line with analyst expectations

Upcoming dividend of NT$1.30 per share at 1.6% yield

Investor sentiment deteriorates as stock falls 16%

Now 26% undervalued after recent price drop

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend for the Year 2022

Now 26% undervalued

Investor sentiment improves as stock rises 15%

Price target increased by 12% to NT$91.50

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to NT$91.40

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$1.30 per share

Now 20% undervalued after recent price drop

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Dividend, Payable on August 18, 2022

Price target decreased to NT$84.63

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Appointment of Kuan Arthur¡G as Independent Director

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Chunghwa Chemical Synthesis & Biotech Co., Ltd., Annual General Meeting, May 25, 2022

Price target increased to NT$103

Third quarter 2021 earnings released: EPS NT$1.09 (vs NT$0.44 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS NT$1.63 (vs NT$4.79 in 2Q 2020)

Upcoming dividend of NT$1.50 per share

First quarter 2021 earnings released: EPS NT$1.27 (vs NT$0.36 in 1Q 2020)

Full year 2020 earnings released: EPS NT$6.86 (vs NT$1.51 in FY 2019)

A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Chunghwa Chemical Synthesis & Biotech Co., Ltd., Annual General Meeting, May 24, 2021

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend

New 90-day low: NT$59.10

Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?

New 90-day low: NT$60.80

The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It

Third quarter 2020 earnings released: EPS NT$0.44

Revenue and earnings miss expectations

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces the Change of Representative of the Company's Legal Person Director

New 90-day high: NT$75.30

New 90-day high - NT$66.50

First half earnings released

Upcoming Dividend of NT$0.80 Per Share